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PURPOSE. To compare the distribution of visual field progression rates in three subgroups of
glaucoma, being primary angle-closure glaucoma (PACG), POAG, and juvenile open-angle
glaucoma (JOAG).
METHODS.We assessed glaucoma patients treated in an Indian tertiary care setting with at least
four visual field assessments. We determined rates from a single eye of each of 525 patients
using linear regression of the summary index mean deviation (MD) over time. The main
outcome measures were the proportions of fast (<1.0 to 2.0 dB/y) and catastrophic (<2
dB/y) visual field progression. Bootstrapped 95% CIs allowed comparison with published data
from a large clinical cohort in Canada.
RESULTS. The combined proportion of fast and catastrophic progressors in our cohort was less
than half that in the Canada dataset (2.3% vs. 5.8%), despite median progression rates differing
by only 0.03 dB/y. PACG, POAG, and JOAG represented 45%, 32%, and 12% of our cohort,
respectively. Baseline MD values were similarly distributed between these subtypes. All
subtypes showed a similar shaped distribution for progression rates, with median progression
rates of 0.03, 0.05, and 0.02 dB/y for PACG, POAG, and JOAG, respectively. Combined
proportions of fast and catastrophic progression rates did not significantly differ between
subtypes.
CONCLUSIONS. Differences in fast and catastrophic visual field progression can exist despite
only small changes in median progression rates, highlighting the importance of considering
the full shape of the progression rate distribution when comparing the risk of devastating
visual field loss.
Keywords: glaucoma, progression rate, visual field, juvenile open angle glaucoma, angle-
closure glaucoma
Most patients with treated glaucoma show rates of visualfield progression substantially slower than 1.0 dB/y,
although a small percentage will show more rapid rates.1–3 A
formal analysis of the distribution of progression rates may be
useful for several reasons. Firstly, knowing the likelihood of
particular progression rates in the population can be used to
constrain rate estimates in individuals, thereby potentially
improving their reliability.4 Distributions of rates can also be
used to calculate the proportion of patients likely to develop
visual impairment in their lifetime.5 An analysis of distributions
can also highlight differences in visual outcomes for glaucoma
patients in different geographic locations.6 Distributional
differences between populations likely reflect, at least in part,
that the proportions of glaucoma subtypes and the presence of
risk factors for rapid progression differ between populations.
For example, rapid visual field progression was more common
in a Swedish hospital-based cohort1 than for similar cohorts
from North America.2,3 This may be due to the large proportion
(38%) of the Swedish cohort that had pseudoexfoliation
glaucoma, which is associated with increased progression
rates.7
Although the distribution of visual field progression rates for
several large datasets from North America and Europe have
been compared recently,6 a greater proportion of glaucoma in
Asia consists of angle-closure glaucoma.8 A recent analysis
found that average visual field progression rates in glaucoma
subtypes, including angle-closure glaucoma, did not significant-
ly differ after adjustment for other covariates (e.g., age, IOP, and
central corneal thickness).9 Such an analysis of average rates
does not address potential differences in progression rate
distributions between subtypes. Distributional differences may
be important, particularly if they occur predominantly in the
distributions’ tails where rapid progressors lie. For example, an
extended tail of fast progressors is seen in pseudoexfoliation
glaucoma.7 Furthermore, even if glaucoma subtype is not an
independent risk factor, differences in progression rates
between subtypes will likely still occur in a clinical setting
due to differences in other risk factors that covary with
glaucoma subtype. For example, pseudoexfoliative glaucoma
was not found to be an independent risk factor for progression
(i.e., when covariates were controlled for in a statistical study),
but patients with pseudoexfoliation progressed more often
than other subtypes (i.e., in a univariate analysis) in part
because pseudoexfolation is associated with significantly
increased mean, peak, and IOP fluctuations relative to these
other subtypes.9
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The distribution of progression rates for one glaucoma
subtype in India has recently been published. Gupta et al.10
analyzed the distribution of visual field progression rates in a
group of juvenile open-angle glaucoma (JOAG) patients from
India, and predicted the likely incidence of perimetric
blindness as such patients aged. These incidences were either
higher or lower than estimates based on a comparison with
published rates for POAG patients from other countries,
highlighting the challenge of comparing rates between
glaucoma subtypes when the subtypes are investigated in
differently constructed studies (e.g., different inclusion and
exclusion criteria, or different regression analysis methods)
performed on geographically differing populations. Such
challenges would be avoided through a comparison of visual
field progression distributions for common glaucoma subtypes,
taken from a single clinical database of patients from a similar
geographic region and subject to a common standard of care.
Here, we analyzed the distribution of visual field progres-
sion rates in a cohort of glaucoma patients from a single
tertiary care setting in India. We also compared progression
rates for common glaucoma subtypes within the cohort,
allowing us to test the hypothesis that predicted visual
impairment in the common subgroup JOAG is greater than
for those with POAG when compared within a similar
geographic and clinical care setting, due to an anticipated
increased residual life expectancy in the former. We also
compared key distributions from our cohort with recently
published data from a tertiary care clinical setting in Canada.3
METHODS
Approval for this retrospective study was provided by the
Ethics Committee of the All India Institute of Medical Sciences,
Delhi. Glaucoma patients treated at Dr. Rajendra Prasad Centre
for Ophthalmic Sciences, AIIMS (a tertiary referral center)
between December 2003 to December 2016 were identified.
Although many thousands of glaucoma patients are seen for a
consultation, the center only provides follow-up care for a
small minority of patients. Approximately 600 glaucoma
patients undergo a perimetric examination at the center each
year, being 5% of the approximately 12,000 glaucoma patients
seen annually. Patients with ocular co-morbidities, except for
mild lenticular sclerosis, were excluded. We initially retrieved
visual field series (Humphrey Field Analyser II 30-2 SITA
Standard; Carl Zeiss Meditec, Dublin, CA, USA) for 1017 eyes
for those patients, after excluding those patients with ocular
co-morbidities other than mild lenticular sclerosis. Unreliable
visual fields (i.e., those with fixation losses >20%, false-positive
rates >15%, and false-negative rates >33%) were excluded
from each series. We then excluded those who had no
diagnostic category (62 eyes), and then those with three or
fewer fields in the series (23 eyes). We then selected a single
eye from each patient (at random, if records from both eyes
were available [407 patients], based on a random number
generation in Excel; Microsoft, Redmond, WA, USA) to form
our cohort of 525 eyes. Glaucoma diagnosis was based on the
diagnostic code given for the selected eye. We then performed
an ordinary least squares regression on the summary index
mean deviation (MD) over time for each patient in order to
determine the rate of visual field progression in decibels per
year. We applied previously described limits of ‘‘fast’’ (<1.0 to
2.0 dB/y) and ‘‘catastrophic’’ (<2.0 dB/y) visual field
progression.3 In addition to the progression rates, the
following data were extracted from the visual field reports:
age at first visual field test, sex, and baseline MD. Where
available, pretreatment IOP was also extracted from patients’
records.
Glaucoma Subtypes
As we wished to analyze glaucoma as classified in a clinical
setting, we identified glaucoma subtypes in our cohort based
on the diagnostic codes entered on the visual field records
rather than by applying a fixed set of inclusion or exclusion
criterion. These codes were assigned by the glaucoma
specialist treating the patient, and then entered by the
perimetrist. Our approach also facilitated comparisons with
recent distributional data from Canada, which similarly used a
clinical classification to select glaucoma patients and glaucoma
suspects.3 We assumed glaucoma was primary if a secondary
cause was not given (e.g., a diagnosis of ‘‘open-angle
glaucoma’’ was assumed to be POAG). We grouped patients
into POAG (persons coded as chronic open-angle glaucoma [n
¼ 1], open-angle glaucoma [4], open-angle glaucoma suspect
[2], POAG [134], or POAG suspect [29]), primary angle-closure
glaucoma (PACG: persons coded as angle-closure glaucoma [3],
angle-closure suspect [1], chronic angle-closure glaucoma [23],
chronic PACG [62], PACG [110], subacute PACG [28], and
subacute angle-closure glaucoma [7]), and JOAG (persons
coded as JOAG [61], and JOAG suspect [4]). These three
classifications made up 89% of our cohort. We did not analyze
other glaucoma subtypes in the remaining 11% due to
insufficient numbers of patients to satisfactorily quantify
distributions.
Statistical Analyses
We performed a nonparametric bootstrap (n ¼ 50,000) to
determine 95% confidence limits around proportions and
median values, using custom software written in Matlab
(R2015a for Macintosh; Mathworks, Natick, MA, USA). When
comparing our cohort data with that of Canada, a proportion
or median was judged to be different when it fell outside the
95% confidence limit of our cohort’s proportion or median. As
our cohort had a sample size less than the Canadian (525 vs.
2324) and so would be expected to have wider confidence
limits, this approach should limit Type I errors.
We also performed a Fisher’s exact test to compare the
combined proportion of fast and catastrophic progressors in
each subgroup. Fast and catastrophic groups were combined
given the low sample numbers, particularly in the catastrophic
progression category. Previous work found a combined
proportion of fast and catastrophic observers of approximately
6% in a Canadian population,3 and 30% in a Swedish
population.1 This 5-fold difference is likely to reflect, at least
in part, the presence of a large subpopulation of pseudoexfo-
liation glaucoma in the Swedish group, as noted earlier.
Assuming a smaller 3-fold difference in combined fast and
catastrophic rates between subtypes in our cohort, we
estimated sample sizes of 125 per subgroup in order to find
this difference (P < 0.05) with a power of 0.80.11 As we
analyzed all available data meeting our inclusion criteria, our
sample sizes were necessarily fixed. Both our POAG and PACG
subgroups substantially exceeded the sample sizes estimated
from our power analysis.
Predicted MD at Life Expectancy
Life expectancy in India is approximately 68 years.12 We
estimated the MD value at this age (MD68) for our cohort using
a linear model:
MD68 ¼ MDbaseline þ 68 baseline ageð Þ3 rate ð1Þ
where MDbaseline was the patient’s initial MD value, baseline
age was the age when visual field testing was commenced, and
rate was the rate of MD progression in dB/y. Simulation work
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has demonstrated that progression rate estimates above þ1.0
dB/y can occur when visual field results are noisy and/or visual
field series are short, despite a patient’s true, underlying
progression rate being below þ1.0 dB/y.13 Such positive
progression rates estimates could potentially produce large,
and unrealistic, improvement in visual fields when extrapolat-
ed over an extended time. Therefore, we capped the maximum
improvement at 2 dB above baseline; this was done for reasons
of physiological plausibility, but does not actually influence our
reported frequencies of visual impairment, which are driven
solely by negative progression rates. One hundred eighteen
eyes (22%) from our cohort had improvements greater than 2
dB that were then capped at 2 dB, consistent with the high
proportion of people with positive progression rates in our
data (see Results). We also capped the minimum MD allowable
to30 dB, and set theMD68 for any patients already 68 years or
older to their baseline MD. We defined visual impairments as an
MD less than 20 dB, being a level previously used to define
visual impairment14 and close to the level used to mark
statutory blindness by Saunders et al.5
RESULTS
Figure 1 shows the distribution of baseline age, MD, number of
visual field examinations, and follow-up duration for the cohort
(histogram bars) along with comparison data from a cohort of
clinical patients from a tertiary care setting in Canada.3 Of note
was the upper half of the baseline age distribution was shifted
left by approximately a decade, consistent with the age
expectancy in India being approximately 14 years less than
in Canada.12 In addition, our cohort contained a more
substantial lower tail of patients older than 40 years. The
median baseline MD was lower for the Canadian dataset, and
lay outside the 95% confidence limit for our cohort data
(Table). The number of examinations was broadly similar,
although the frequency distribution of follow-up years was
shifted to the left for the Canadian dataset, consistent with
visual fields being performed more frequently for that group.
The distribution of progression rates is shown in Figure 2. A
linear regression showed a significant relationship between age
and progression rate for our cohort, with a regression slope of
0.047 dB/decade (P < 0.001). A similar linear regression
found no significant relationship between baseline MD and rate
of progression (slope 0.003, P ¼ 0.21). The median rate, and
proportion of fast and catastrophic progressors, for the
Canadian dataset fell outside the 95% confidence limits for
our cohort, with the Canadian group showing faster median
progression, and a larger proportion of fast and catastrophic
progressors (Table). Given the median age for the Canadian
group was 12 years greater than for our cohort (Table), along
with the significant relationship between age and progression
rate we found, we modelled what might be the proportion of
fast and catastrophic progressors if our cohort were 12 years
older (i.e., if progression rates were all adjusted by0.056 dB/y
[¼ 1.2 decades 30.047 dB/decade]). The proportion of fast
and catastrophic progressors in this adjusted data was 3.24
FIGURE 1. Distributions of baseline age (A), baseline MD (B), number of visual field examinations (C), and follow-up duration (D) for a cohort of
525 patients from India. Lower limits of the histogram bins are applied inclusively. Unfilled circles and lines show data from a large clinical
population in Canada, as visually estimated from figures presented in Chauhan et al.,3 where the symbol gives the height of each bin’s midpoint. Of
note is follow-up frequencies for the Canadian dataset are in half-yearly, rather than yearly, bins, and so would be expected to be half as high.
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(95% CI: 1.90–4.76) and 0.57 (0.00–1.33), respectively, which
are similar to those in the Canadian group.
The most common glaucoma subtype in our cohort was
PACG (45%), followed by POAG (32%) and JOAG (12%).
Although we did not extract data for our particular cohort, we
estimate that 18% of POAG patients, 32% of PACG patients, and
no JOAG patients, are pseudophakic at baseline in our hospital.
The distribution of baseline age, MD, number of visual field
examinations, and follow-up duration for these subgroups can
be seen in Figure 3. Overall, there was little difference between
subgroups, except for the marked shift in the age distribution
seen in JOAG. Compared with PACG, neither POAG (P¼ 0.73)
nor JOAG (P ¼ 0.18) had a significantly increased combined
proportion of fast and catastrophic progressors (Fisher’s exact
test; Fig. 4), and this combined proportion was not associated
with the length of the visual field series (Supplementary Table
S1).
As JOAG patients were significantly younger (Table), yet had
similar rates of visual field progression to other glaucoma
subtypes (Fig. 4) and similar baseline MD values (Fig. 3), it
would be anticipated that a greater proportion of these
patients would have an MD less than 20 dB at 68 years (i.e.,
have visual impairment). The proportion of glaucoma subtypes
with a MD68 less than20 dB was 10% (18/170), 6% (13/234),
and 27% (17/64) for POAG, PACG, and JOAG, respectively. The
proportions were significantly different (X2 [23.53, 2], P <
0.0001). Subsequent paired Fisher tests found the proportion
for JOAG was significantly higher compared with both POAG
(P¼ 0.004) and PACG (P < 0.0001), but that POAG and PACG
did not significantly differ (P ¼ 0.09).
DISCUSSION
We found that our three glaucoma subtypes, POAG, PACG and
JOAG, had similar median progression rates, and comparable
levels of visual field loss at baseline (Table). This finding is
similar to that reported by De Moraes et al.2 where there was
no difference in the average rate of visual field progression
between these subgroups for a US-based cohort. Although De
Moraes et al.2 did find that pseudoexfoliation glaucoma gave
significantly higher rates of visual field progression in their
univariate analysis, this association was no longer significant
after adjusting for covariates. With regard to POAG and PACG
cohorts drawn from India, our findings agree with those of Rao
et al.15 who did not find significant differences in progression
rates between POAG and PACG among patients from SouthernT
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FIGURE 2. Distribution of rates of visual field progression. Data
estimated from Chauhan et al.,3 is given in comparison (unfilled
circles).
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India. Increased rates of visual field loss in PACG compared
with POAG in a Korean cohort have been reported by Lee et
al.16 based on gradings of Goldmann visual fields, although of
note is that their PACG patients had significantly higher
number of surgeries and had significantly higher IOP through-
out the study, compared with their POAG patients. In our
clinical setting, PACG patients are generally treated with
surgery earlier, using either a cataract extraction or filtering
surgery. This higher rate of early surgical intervention may
explain why we do not predict a greater level of visual
impairment in PACG compared with POAG in our current
study, in contrast to the greater blindness found from PACG
compared with POAG in population-based studies.17–19
Proportion of Fast and Catastrophic Progression
in Glaucoma Subtypes
Based on our results, we believe that giving the proportion of
fast (<1.0 to 2.0 dB/y) and catastrophic (<2 dB/y)
progressors may be a more meaningful summary statistic for
rate-of-change distributions than the median rate of change.
Identification of rapid progressors is important for stratification
of resources toward this small population of patients. Boodhna
et al.20 found that while overall progression rates have
improved over the years due to better management of
glaucoma, the prevalence of rapid progressors remained
unchanged, indicating that preserving vision in such patients
remains a significant clinical challenge. The proportion of
catastrophic rates of progression in our cohort was slightly
lower than that from Canada,3 and were substantially lower
than those from a hospital-based cohort in Southern Sweden1
(fast ~30%, catastrophic ~9%) which is likely due to the
substantial proportion of fast progressing pseudoexfoliation
glaucoma in this latter cohort.
The proportion of fast and catastrophic progressors in the
Canada dataset was over double that for our cohort (5.8% vs.
2.3%), despite median progression rates differing by only 0.03
dB/y. This highlights how a comparison of median progression
rates may not reflect behavior in the tails of progression rate
distributions. It is unlikely that this difference is attributable to
increased noise in the Canadian dataset artificially broadening
the tails of the distribution, and so increasing the proportion of
FIGURE 3. Distributions of baseline age (A), baseline MD (B), number of visual field examinations (C), and follow-up duration (D) for cohorts with
POAG, PACG, and JOAG. Remaining details are as given in Figure 1.
FIGURE 4. Distribution of rates of visual field progression for persons
with POAG, PACG, and JOAG.
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fast and catastrophic progressors. The Canadian study em-
ployed a robust regression method, in contrast to the more
common ordinary least-squares method we employed, and had
a larger sample size than our study. Both of these factors should
reduce noise, and so should produce a narrower distribution of
progression rates13 rather than the broader-tailed distribution
we found. When we adjusted our cohort to account for the 12-
year age difference between our cohort and that from Canada,
proportions of fast and catastrophic progressors become
similar. Although an interesting finding, we caution against
concluding that the difference in rates between our groups is
therefore due to age. While the groups differ substantially in
terms of absolute age, they are reasonably well matched in
terms of age relative to life expectancy. Increasing age has been
found by some to increase the rate of visual field loss within a
given population,21–23 although the validity of using this
relationship to adjust for age differences between populations
with different life expectancies remains necessarily specula-
tive.
Our comparison of glaucoma subtypes revealed no signif-
icant difference in the combined rates of fast and catastrophic
progressors. Importantly, these comparisons were made
between subgroups drawn from within a single cohort of
shared geography (Northern India) and subject to similar
standards of care (a single hospital-based setting), thereby
avoiding the challenges faced when trying to compare
progression rate distributions in subgroups drawn from
different studies.10 With regard to our POAG subgroup, we
did not show a significant increase in the proportion showing
visual impairment (MD <20 dB) at life expectancy compared
with PACG. Such longitudinal analysis stands in contrast to the
findings of Garudadri et al.,18 who found a greater proportion
of blindness from PACG than POAG in a cross-sectional study in
India. The large majority of people in their study were
previously unaware of their disease, and so the difference
between our results and theirs may in part reflect differences
between the natural and treated histories of PACG versus
POAG.
Rate of VF Loss Overall
Our results show that the overall visual field progression rates
for our cohort were similar to what has been reported from a
Canadian tertiary care setting.3 Our median rate of visual field
loss was just outside the interquartile range (IQR) previously
reported by Rao et al.24 for an Indian population (0.19 dB/y:
IQR 0.41, 0.03) and so is likely within the 95% CI
(unreported) for their data, despite their cohort having a
substantially greater median MD at baseline (16.9 vs. 4.42).
This is consistent with the observation that baseline MD does
not profoundly affect rate of visual field progression,3,24
although floor effects will likely slow measured progression
rates in those with advanced field loss.24
Predicted Visual Impairment
We found that fewer than 0.5% of patients were above 80 years
at diagnosis, compared with approximately 9% in Canada.3 The
main portion of the age distribution was shifted leftward in our
cohort by an amount similar to the expected life-expectancy
difference between India and Canada (68.3 vs. 82.2 years).12 As
such, the residual life expectancy for POAG and PACG patients
after diagnosis might be expected to be similar between both
countries. However, a slightly greater level of visual impair-
ment over their residual life expectancy might be expected in
our cohort as baseline MDs were approximately 2 dB worse. It
should also be noted that our estimation of life expectancy is
necessarily approximate, and could be improved by incorpo-
rating patient sex, as well as patient age so that changes in life
expectancy rates over time are accounted for. However, the
principal limitation in our method for estimating vision
impairment at life expectancy is almost certainly not our
estimate of life expectancy itself, but rather the rate of visual
field loss visual used in our extrapolation.
Patients with JOAG would be expected to have an increased
residual life expectancy: correspondingly, our calculations
predicted that a significantly larger proportion would suffer
substantial visual impairment in their lifetime. Previous
modeling work has suggested that patients with JOAG might
have a similar risk of visual impairment (defined as 50% on
the visual field index) over their lifetime compared with other
forms of glaucoma.10 The conclusions of previous modeling
were made based on comparisons to rates from other
published studies. That the methodology in our current study
avoids the potentially large between-study variations noted
above may, in part, explain the difference between the current
and previous10 findings. In general, any such modeling should
be treated with a certain degree of caution as it assumes that a
patient’s visual field damage will progress at a constant rate
across their lifetime, even if therapeutic interventions are
subsequently altered. In addition, estimates of the rate of
progression are subject to substantial noise particularly when
visual field series are short,25 which can act to artefactually
broaden the distribution of visual field progression rates.13
Such noise might be expected to be slightly greater in the
current study than in previous work as we allowed shorter
visual field series (minimum 4 vs. 5) and had no minimum
follow-up time (compared with a minimum 5 years in Gupta et
al.10). Despite these caveats, our results do not appear out of
step with empirical findings. We predicted visual impairment
among PACG eyes to be 6% in our cohort over approximately
11.5 years (which is life expectancy minus median age at
baseline). This is similar to that determined empirically by
Quek et al.26 who found 7% of eyes progressing to blindness
among Chinese patients with treated PACG over 10 years
(using a definition of blindness based on the presence of
sensitivity 10 dB at or within 208 fixation, and/or visual acuity
of 20/200 or worse). The level of the impairment for the
patient is more difficult to estimate, and will be reduced if the
visual field of their fellow eye is less severely damaged. A
limitation of our study is that our extracted data did not include
information on the state of the fellow eye for those participants
who only had monocular visual fields available. While it is
possible that some of these patients had monocular testing due
to only monocular disease being manifest, it is also possible
that some had severe visual impairment or blindness that
precluded visual field assessment. A further limitation is that
patients with severe vision loss or blindness upon presentation
are unlikely to be those provided follow-up care with
perimetry within our hospital, and so will necessarily not be
represented in the selection of patients we analyzed. As such,
our cohort represents a selected sample that isolates those
patients who have been followed perimetrically. This is,
however, the group for whom knowing the rate of visual field
progression—and, therefore, the likelihood of significant visual
impairment in their lifetimes—is probably most critical.
In summary, we show that differences in fast and
catastrophic visual field progression may occur between
cohorts with similar median progression rates, and that three
common glaucoma subtypes within a single cohort have
similar rates of fast and catastrophic progression. These results
highlight the importance of considering the full shape of the
distribution when assessing progression rates, as patients with
rapidly deteriorating fields are among those whose manage-
ment is the most challenging and urgent.
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